SCOPUS 정보 검색 플랫폼

Volumn 4, Issue 11, 2015, Pages

Natural killer cell mediated immunosurveillance of pediatric neuroblastoma

(4) Semeraro, Michaela a,b,c,d,e Rusakiewicz, Sylvie a,b,c,d,e Zitvogel, Laurence a,b,c,d,e Kroemer, Guido a,b,c,d,e,f,g,h

a INSTITUT GUSTAVE ROUSSY (France)

b University Paris XI (France)

c GRCC (France)

d UNIVERSITÉ PARIS SACLAY (France)

e CENTRE DE RECHERCHE DES CORDELIERS (France)

f UNIVERSITÉ PARIS DESCARTES (France)

g SORBONNE UNIVERSITÉ (France)

h HÔPITAL EUROPÉEN GEORGES POMPIDOU (France)

Author keywords

immunosurveillance; neuroblastoma; NK cells; NKp30; pediatric cancer

Indexed keywords

CD16 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; TUMOR NECROSIS FACTOR ALPHA;

ALTERNATIVE RNA SPLICING; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BONE MARROW METASTASIS; DOWN REGULATION; GAIN OF FUNCTION MUTATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOSURVEILLANCE; NATURAL KILLER CELL; NEUROBLASTOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR REGRESSION;

EID: 84941777829 PISSN: 21624011 EISSN: 2162402X Source Type: Journal
DOI: 10.1080/2162402X.2015.1042202 Document Type: Article

Times cited : (33)

References (10)

1
- 84927585373
- Innate immune recognition of cancer
- 25622193
- S.R.Woo, L.Corrales, T.F.Gajewski. Innate immune recognition of cancer. Annu Rev Immunol 2015; 33:445-74; PMID:25622193; http://dx.doi.org/10.1146/annurev-immunol-032414-112043
- (2015) Annu Rev Immunol , vol.33 , pp. 445-474
- Woo, S.R.¹ Corrales, L.² Gajewski, T.F.³

2
- 78650970845
- Innate or adaptive immunity? The example of natural killer cells
- 21212348
- E.Vivier, D.H.Raulet, A.Moretta, M.A.Caliguri, L.Zitvogel, L.L.Lanier, W.M.Yokoyama, S.Ugolini. Innate or adaptive immunity? The example of natural killer cells. Science 2011; 331:44-9; PMID:21212348; http://dx.doi.org/10.1126/science.1198687
- (2011) Science , vol.331 , pp. 44-49
- Vivier, E.¹ Raulet, D.H.² Moretta, A.³ Caliguri, M.A.⁴ Zitvogel, L.⁵ Lanier, L.L.⁶ Yokoyama, W.M.⁷ Ugolini, S.⁸

3
- 84880747672
- Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance
- 23890065
- L.Zitvogel, L.Galluzzi, M.J.Smyth, G.Kroemer. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39:74-88; PMID:23890065; http://dx.doi.org/10.1016/j.immuni.2013.06.014
- (2013) Immunity , vol.39 , pp. 74-88
- Zitvogel, L.¹ Galluzzi, L.² Smyth, M.J.³ Kroemer, G.⁴

4
- 84886944930
- Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome
- 23525357
- N.Chaput, C.Flament, C.Locher, M.Desbois, A.Rey, S.Rusakiewicz, V.Poirier-Colame, P.Pautier, A.Le Cesne, J.C.Soria et al. Phase I clinical trial combining imatinib mesylate and IL-2: HLA-DR NK cell levels correlate with disease outcome. Oncoimmunology 2013; 2:e23080; PMID:23525357; http://dx.doi.org/10.4161/onci.23080
- (2013) Oncoimmunology , vol.2
- Chaput, N.¹ Flament, C.² Locher, C.³ Desbois, M.⁴ Rey, A.⁵ Rusakiewicz, S.⁶ Poirier-Colame, V.⁷ Pautier, P.⁸ Le Cesne, A.⁹ Soria, J.C.¹⁰

5
- 79958118266
- Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors
- 21552268
- N.F.Delahaye, S.Rusakiewicz, I.Martins, C.Menard, S.Roux, L.Lyonnet, P.Paul, M.Sarabi, N.Chaput, M.Semeraro et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med 2011; 17:700-7; PMID:21552268; http://dx.doi.org/10.1038/nm.2366
- (2011) Nat Med , vol.17 , pp. 700-707
- Delahaye, N.F.¹ Rusakiewicz, S.² Martins, I.³ Menard, C.⁴ Roux, S.⁵ Lyonnet, L.⁶ Paul, P.⁷ Sarabi, M.⁸ Chaput, N.⁹ Semeraro, M.¹⁰

6
- 84879100801
- Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors
- 23592754
- S.Rusakiewicz, M.Semeraro, M.Sarabi, M.Desbois, C.Locher, R.Mendez, N.Vimond, A.Concha, F.Garrido, N.Isambert et al. Immune infiltrates are prognostic factors in localized gastrointestinal stromal tumors. Cancer Res 2013; 73:3499-510; PMID:23592754; http://dx.doi.org/10.1158/0008-5472.CAN-13-0371
- (2013) Cancer Res , vol.73 , pp. 3499-3510
- Rusakiewicz, S.¹ Semeraro, M.² Sarabi, M.³ Desbois, M.⁴ Locher, C.⁵ Mendez, R.⁶ Vimond, N.⁷ Concha, A.⁸ Garrido, F.⁹ Isambert, N.¹⁰

7
- 84882999456
- NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome
- 23884468
- S.Rusakiewicz, G.Nocturne, T.Lazure, M.Semeraro, C.Flament, S.Caillat-Zucman, D.Sene, N.Delahaye, E.Vivier, K.Chaba et al. NCR3/NKp30 contributes to pathogenesis in primary Sjogren's syndrome. Sci Transl Med 2013; 5:195ra96; PMID:23884468; http://dx.doi.org/10.1126/scitranslmed.3005727
- (2013) Sci Transl Med , vol.5 , pp. 195-196
- Rusakiewicz, S.¹ Nocturne, G.² Lazure, T.³ Semeraro, M.⁴ Flament, C.⁵ Caillat-Zucman, S.⁶ Sene, D.⁷ Delahaye, N.⁸ Vivier, E.⁹ Chaba, K.¹⁰

8
- 84886943438
- Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort
- 23802087
- N.Prada, G.Antoni, F.Como, S.Rusakiewicz, M.Semeraro, F.Boufassa, O.Lambotte, L.Meyer, M.L.Gougeon, L.Zitvogel. Analysis of NKp30/NCR3 isoforms in untreated HIV-1-infected patients from the ANRS SEROCO cohort. Oncoimmunology 2013; 2:e23472; PMID:23802087; http://dx.doi.org/10.4161/onci.23472
- (2013) Oncoimmunology , vol.2
- Prada, N.¹ Antoni, G.² Como, F.³ Rusakiewicz, S.⁴ Semeraro, M.⁵ Boufassa, F.⁶ Lambotte, O.⁷ Meyer, L.⁸ Gougeon, M.L.⁹ Zitvogel, L.¹⁰

9
- 84928253171
- Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients
- 25877893
- M.Semeraro, S.Rusakiewicz, V.Minard-Colin, N.F.Delahaye, D.Enot, F.Vély, A.Marabelle, B.Papoular, C.Piperoglou, M.Ponzoni et al. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med 2015; 7:283ra55; PMID:25877893; http://dx.doi.org/10.1126/scitranslmed.aaa2327
- (2015) Sci Transl Med , vol.7 , pp. 255-283
- Semeraro, M.¹ Rusakiewicz, S.² Minard-Colin, V.³ Delahaye, N.F.⁴ Enot, D.⁵ Vély, F.⁶ Marabelle, A.⁷ Papoular, B.⁸ Piperoglou, C.⁹ Ponzoni, M.¹⁰

10
- 84918591464
- Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma
- 25351955
- L.Ferrari de Andrade, S.F.Ngiow, K.Stannard, S.Rusakiewicz, M.Kalimutho, K.K.Khanna, S.K.Tey, K.Takeda, L.Zitvogel, L.Martinet et al. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res 2014; 74:7298-308; PMID:25351955; http://dx.doi.org/10.1158/0008-5472.CAN-14-1339
- (2014) Cancer Res , vol.74 , pp. 7298-7308
- Ferrari de Andrade, L.¹ Ngiow, S.F.² Stannard, K.³ Rusakiewicz, S.⁴ Kalimutho, M.⁵ Khanna, K.K.⁶ Tey, S.K.⁷ Takeda, K.⁸ Zitvogel, L.⁹ Martinet, L.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.